In their article, Scott, Anderson, and Peter Kuhn, Ph.D., associate professor in the department of cell biology at the Scripps Research Institute Physical Sciences-Oncology Center in La Jolla, Calif., wrote that although Paget's seed-soil hypothesis suggests that both the site of a metastasis (the soil) and the metastatic cells (the seed) are necessary for metastasis to occur, how seeds are disseminated to specific soil remains a puzzle. "We think that it is during this poorly understood phase of metastasis that we can answer some important questions," said Scott.
In theory, until the evolution of a suitable seed, any number of CTCs could flow through the circulation and arrest at end organs without forming metastases, Scott continued. Because tumor heterogeneity is thought to expand with tumor progression, at some point a seed suited to a specific soil within that patient's body will develop. The seed must find its soil.
"We think this process is governed by solvable physical rules that relate to the dynamics of the circulatory flow between different organs and how these organs filter," said Scott. "Although these biological mechanisms are not yet known, we might be able to infer their existence by finding out which measurements do not fit a model that is defined only by physical flow and filtration."
Understanding Cancer With Physics and Mathematics
That's where mathematical modeling comes in, which though not new in cancer research has perhaps been underrepresented, according to some experts. Larry Norton, M.D., medical director of the Evelyn H. Lauder Breast Center at Memorial Sloan-Kettering Cancer Center in New York, has long believed that more mathematics is needed to better understand and develop better cancer therapies. Specifically, Norton has said that oncologists should spend more time devising equations that explain how fast tumors grow, how quickly cancer cells develop resistance to therapy, and how often they metastasize.
Larry A. Nagahara, Ph.D., director of the Office of Physical Sciences-Oncology at the National Cancer Institute, said that mathematicians, physicists, and engineers can bring new perspectives to understand cancer. "I think by having a diverse group of disciplines, we can get some fresh views and contribute to our understanding." Earlier this year, Nagahara served as scientific adviser on the Physics and Mathematics of Cancer workshops held at the Kavli Institute for Theoretical Physics in Santa Barbara, Calif. The workshops focused on physical and mathematical models of tumor initiation, progression, and metastases, as well as developing new physical probes of cancers.
Quantifying Biological Processes
Scott, who is working on a Ph.D. in mathematics at the University of Oxford Centre, and colleagues propose four key biological processes that could be quantified:
1. The rate at which the tumor sheds CTCs into the vasculature 2. The CTC phenotypic heterogeneity, defined as the distribution of CTC phenotypes present in the circulation 3. The filtration fraction (the proportion and type of CTCs "arrested" in a given organ) 4. How quickly CTCs are cleared from the blood or organ after arrest (Scott noted that they didn't invent these concepts. "These are all things that have been studied by different people over the last 30 or 40 years.") According to Scott, developing a mathematical model will help define both the concentration of CTCs and their phenotypic distribution at any given point in the network, as well as organ-specific filtration values. "We recognize that each of these biological processes is probably disease-and even patient-specific," he said. To parameterize this model, Scott said, researchers will need to characterize and count CTCs taken from one patient at different times and from different points in this network.
A complete understanding of the model will also yield information about the behavior of the system as a whole, Scott continued. Specifically, researchers will be able to calculate the average lifespan of a CTC in a patient's circulation with minimal measurements. "Although this seems to be a simple calculation, the scientific literature on this topic is substantially conflicted, with reports of cells lasting on the order of years in some patients but less than 24 hours in others," said Scott.
The researchers wrote that even this seemingly simple factor will differ between patients and cancer types and will lead to many questions:
• Could there be a "circulator" phenotype that avoids arrest with extreme efficiency that can explain long dormancy periods?
• Could this cell type be targeted?
• Could such a cell type be mechanically filtered out?
"This example," they wrote, "represents one of the many new pieces of information that we are on the brink of understanding through mathematical models that could inform treatment decision-making paradigms."
Ann F. Chambers, Ph.D., Canada research chair and oncology professor at the University of Western Ontario, applauds their efforts to better understand metastases. However, she disputes some of their findings. "The authors propose that there may be a CTC 'circulator' phenotype that would enable CTCs to survive in the circulation for years," said Chambers. "However, the available evidence suggests that an individual CTC's half-life in the circulation is on the order of minutes to hours. There is no evidence that individual CTCs can survive for years in the circulation."
Even so, Chambers said the authors have synthesized from the literature many key factors that deserve further study and measurement. "This is great, because we need physi cists and other disciplines to think about this kind of stuff. Overall, I believe it will contribute to a better understanding of metastases."
